Epitope discovery and their use in peptide based vaccines

Current Pharmaceutical Design

Volumn 16, Issue 28, 2010, Pages 3149-3157

  Dudek, Nadine L ^a   Perlmutter, Patrick ^b   Aguilar, Marie Isabel ^b   Croft, Nathan P ^a   Purcell, Anthony W ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Antigen processing; Epitope discovery; Epitope validation; Major histocompatibility complex; Peptide epitope

Indexed keywords

EPITOPE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE VACCINE; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR AGONIST;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN STRUCTURE; AUTOIMMUNITY; BINDING AFFINITY; CD8+ T LYMPHOCYTE; CELL STIMULATION; CHEMICAL MODIFICATION; CHRONIC DISEASE; CLINICAL TRIAL; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; GENE FREQUENCY; GENETIC VARIABILITY; HEPATITIS C; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEOMICS; REVIEW; T LYMPHOCYTE ACTIVATION; VALIDATION PROCESS; VIRUS IMMUNITY; VIRUS INFECTION;

DRUG DISCOVERY; EPITOPES; HLA ANTIGENS; HUMANS; MODELS, IMMUNOLOGICAL; NEOPLASMS; PEPTIDES; T-LYMPHOCYTES; VACCINES, SUBUNIT; VIRUS DISEASES;

EID: 78649841078     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793292447     Document Type: Review

References (139)

1. Purcell AW, Zeng W, Mifsud NA, Ely LK, Macdonald WA, Jackson DC. Dissecting the role of peptides in the immune response: theory, practice and the application to vaccine design. J Pept Sci 2003; 9: 255-281.
2. Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 2007; 6: 404-414.
3. Reits E, Griekspoor A, Neijssen J, et al. Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC Class I. Immunity 2003; 18: 97-108.
4. Ely LK, Burrows SR, Purcell AW, Rossjohn J, McCluskey J. Tcells behaving badly: structural insights into alloreactivity and autoimmunity. Curr Opin Immunol 2008; 20: 575-580.
5. Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides and. Ann Rev Immunol 2006; 24: 419-466.
6. http: //www-bimas.cit.nih.gov/molbio/hla_bind/ on World Wide Web URL:
7. Donnes P, Elofsson A. Prediction of MHC class I binding peptides, using SVMHC. BMC Bioinformatics 2002; 3: 25.
8. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50: 213-219.
9. Sieker F, May A, Zacharias M. Predicting affinity and specificity of antigenic peptide binding to major histocompatibility class I molecules. Curr Protein Pept Sci 2009; 10: 286-296.
10. Tong JC, Tan TW, Ranganathan S. Methods and protocols for prediction of immunogenic epitopes. Brief Bioinform 2007; 8: 96-108.
11. Chang L, Kjer-Nielsen L, Flynn S, et al. Novel strategy for identification of candidate cytotoxic T-cell epitopes from human preproinsulin. Tiss Antigens 2003; 62: 408-417.
12. Buus S. Description and prediction of peptide-MHC binding: the 'human MHC project'. Curr Opin Immunol 1999; 11: 209-213.
13. Engelhard VH, Altrich-Vanlith M, Ostankovitch M, Zarling AL. Post-translational modifications of naturally processed MHCbinding epitopes. Curr Opin Immunol 2006; 18: 92-97.
14. Andersen MH, Tan L, Sondergaard I, Zeuthen J, Elliott T, Haurum JS. Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules. Tiss Antigens 2000; 55: 519-531.
15. Kuckelkorn U, Ruppert T, Strehl B, et al. Link between organspecific antigen processing by 20S proteasomes and CD8(+) T cellmediated autoimmunity. J Exp Med 2002; 195: 983-990.
16. Del-Val M, Lopez D. Multiple proteases process viral antigens for presentation by MHC class I molecules to CD8(+) T lymphocytes. Mol Immunol 2002; 39: 235-247.
17. Burrows SR, Rossjohn J, McCluskey J. Have we cut ourselves too short in mapping CTL epitopes? Trends Immunol 2005; 27: 11-16.
18. Tynan FE, Burrows SR, Buckle AM, et al. T cell receptor recognition of a 'super-bulged' major histocompatibility complex class Ibound peptide. Nat Immunol 2005; 6: 1114-1122.
19. Tynan FE, Reid HH, Kjer-Nielsen L, et al. A T cell receptor flattens a bulged antigenic peptide presented by a major histocompatibility complex class I molecule. Nat Immunol 2007; 8: 268-276.
20. Mannering SI, Harrison LC, Williamson NA, et al. The insulin Achain epitope recognized by human T cells is posttranslationally modified. J Exp Med 2005; 202: 1191-1197.
21. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Ann Rev Immunol 1999; 17: 51-88.
22. Lin H, Ray S, Tongchusak S, Reinherz E, Brusic V. Evaluation of MHC class I peptide binding prediction servers: Applications for vaccine research. BMC Immunol 2008; 9: 8.
23. Rammensee HG. Chemistry of peptides associated with MHC class I and class II molecules. Curr Opin Immunol 1995; 7: 85-96.
24. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Ann Rev Immunol 1997; 15: 821-850.
25. Luft T, Rizkalla M, Tai TY, et al. Exogenous peptides presented by transporter associated with antigen processing (TAP)-deficient and TAP-competent Cells: intracellular loading and kinetics of presentation. J Immunol 2001; 167: 2529-2537.
26. Rock KL, Shen L. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol Rev 2005; 207: 166-183.
27. Zehn D, Cohen CJ, Reiter Y, Walden P. Efficiency of peptide presentation by dendritic cells compared with other cell types: implications for cross-priming. Int Immunol 2006; 18: 1647-1654.
28. Webb AI, Dunstone MA, Williamson NA, et al. T cell determinants incorporating {beta}-amino acid residues are protease resistant and remain immunogenic in vivo. J Immunol 2005; 175: 3810-3818.
29. Day EB, Zeng W, Doherty PC, Jackson DC, Kedzierska K, Turner SJ. The context of epitope presentation can influence functional quality of recalled influenza A virus-specific memory CD8+ T cells. J Immunol 2007; 179: 2187-2194.
30. Ireland J, Herzog J, Unanue ER. Cutting edge: unique t cells that recognize citrullinated peptides are a feature of protein immunization. J Immunol 2006; 177: 1421-1425.
31. Van den Steen PE, Proost P, Brand DD, Kang AH, Van Damme J, Opdenakker G. Generation of glycosylated remnant epitopes from human collagen type II by gelatinase B. Biochemistry 2004; 43: 10809-10816.
32. Backlund J, Carlsen S, Hoger T, et al. Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. Proc Natl Acad Sci USA 2002; 99: 9960-9965.
33. Anderson RP, Degano P, Godkin AJ, Jewell DP, Hill AV. In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nat Med 2000; 6: 337-342.
34. Cao L, Goodin R, Wood D, Moscarello MA, Whitaker JN. Rapid release and unusual stability of immunodominant peptide 45-89 from citrullinated myelin basic protein. Biochemistry 1999; 38: 6157-6163.
35. Speir JA, Abdel-Motal UM, Jondal M, Wilson IA. Crystal structure of an MHC class I presented glycopeptide that generates carbohydrate-specific CTL. Immunity 1999; 10: 51-61.
36. Haurum JS, Arsequell G, Lellouch AC, et al. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. J Exp Med 1994; 180: 739-744.
37. Meadows L, Wang W, den Haan JM, et al. The HLA-A*0201- restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 1997; 6: 273-281.
38. Skipper JC, Hendrickson RC, Gulden PH, et al. An HLA-A2- restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 1996; 183: 527-534.
39. McAdam SN, Fleckenstein B, Rasmussen IB, et al. T cell recognition of the dominant I-A(k)-restricted hen egg lysozyme epitope: critical role for asparagine deamidation. J Exp Med 2001; 193: 1239-1246.
40. van Stipdonk MJ, Willems AA, Amor S, et al. T cells discriminate between differentially phosphorylated forms of alphaB-crystallin, a major central nervous system myelin antigen. Int Immunol 1998; 10: 943-950.
41. Chen W, Ede NJ, Jackson DC, McCluskey J, Purcell AW. CTL recognition of an altered peptide associated with asparagine bond rearrangement. Implications for immunity and vaccine design. J Immunol 1996; 157: 1000-1005.
42. Griffiths HR. Is the generation of neo-antigenic determinants by free radicals central to the development of autoimmune rheumatoid disease? Autoimmunity Rev 2008; 7: 544-549.
43. Purcell AW, Elliott T. Molecular machinations of the MHC-I peptide loading complex. Curr Opin Immunol 2008; 20: 75-81.
44. Mohammed F, Cobbold M, Zarling AL, et al. Phosphorylationdependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self. Nat Immunol 2008; 9: 1236-1243.
45. Petersen J, Wurzbacher SJ, Williamson NA, et al. Phosphorylated self-peptides alter human leukocyte antigen class I-restricted antigen presentation and generate tumor-specific epitopes. Proc Natl Acad Sci USA 2009; 106: 2776-2781.
46. Purcell AW, van Driel IR, Gleeson PA. Impact of glycans on T-cell tolerance to glycosylated self-antigens. Immunol Cell Biol 2008; 86: 574-579
47. Hill JA, Bell DA, Brintnell W, et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med 2008; 205: 967-979.
48. Anderton SM. Post-translational modifications of self antigens: implications for autoimmunity. Curr Opin Immunol 2004; 16: 753-758.
49. Williamson NA, Rossjohn J, Purcell AW. Tumors reveal their secrets to cytotoxic T cells. Proc Natl Acad Sci USA 2006; 103: 14649-14650.
50. Zarling AL, Polefrone JM, Evans AM, et al. Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. Proc Natl Acad Sci USA 2006; 103: 14889-14894.
51. Petersen J, Purcell AW, Rossjohn J. Post-translationally modified T cell epitopes: immune recognition and immunotherapy. J Mol Med 2009; 87: 1045-1051.
52. Zarling AL, Ficarro SB, White FM, Shabanowitz J, Hunt DF, Engelhard VH. Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo. J Exp Med 2000; 192: 1755-1762.
53. Hanada K-I, Yewdell JW, Yang JC. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 2004; 427: 252-256.
54. Vigneron N, Stroobant V, Chapiro J, et al. An antigenic peptide produced by peptide splicing in the proteasome. Science 2004; 304: 587-590.
55. Saska I, Craik DJ. Protease-catalysed protein splicing: a new posttranslational modification? Trends in Biochemical Sciences 2008; 33: 363-368.
56. Kloetzel PM, Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 2004; 16: 76-81.
57. Rock KL, York IA, Goldberg AL. Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat Immunol 2004; 5: 670-677.
58. Kloetzel PM. Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII. Nat Immunol 2004; 5: 661-669.
59. Guil S, Rodriguez-Castro M, Aguilar F, Villasevil EM, Anton LC, Del Val M. Need for tripeptidyl-peptidase II in major histocompatibility complex class I viral antigen processing when proteasomes are detrimental. J Biol Chem 2006; 281: 39925-39934.
60. Kanaseki T, Blanchard N, Hammer GE, Gonzalez F, Shastri N. ERAAP synergizes with MHC class I molecules to make the final cut in the antigenic peptide precursors in the endoplasmic reticulum. Immunity 2006; 25: 795-806.
61. Hammer GE, Gonzalez F, Champsaur M, Cado D, Shastri N. The aminopeptidase ERAAP shapes the peptide repertoire displayed by major histocompatibility complex class I molecules. Nat Immunol 2006; 7: 103-112.
62. Serwold T, Gonzalez F, Kim J, Jacob R, Shastri N. ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 2002; 419: 480-483.
63. Ninkovic T, Hanisch FG. O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes. J Immunol 2007; 179: 2380-2388.
64. Brooks AG, Campbell PL, Reynolds P, Gautam AM, McCluskey J. Antigen presentation and assembly by mouse I-Ak class II molecules in human APC containing deleted or mutated HLA DM genes. J Immunol 1994; 153: 5382-5392.
65. Purcell AW. The peptide-loading complex and ligand selection during the assembly of HLA class I molecules. Mol Immunol 2000; 37: 483-492.
66. Purcell AW, Gorman JJ, Garcia-Peydro M, et al. Quantitative and qualitative influences of tapasin on the class I peptide repertoire. J Immunol 2001; 166: 1016-1027.
67. Sesma L, Galocha B, Vazquez M, et al. Qualitative and quantitative differences in peptides bound to HLA-B27 in the presence of mouse versus human tapasin define a role for tapasin as a sizedependent peptide editor. J Immunol 2005; 174: 7833-7844.
68. Ackerman AL, Kyritsis C, Tampe R, Cresswell P. Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proc Natl Acad Sci USA 2003; 100: 12889-12894.
69. Macdonald WA, Purcell AW, Mifsud NA, et al. A naturally selected dimorphism within the HLA-B44 supertype alters class I structure, peptide repertoire, and T cell recognition. J Exp Med 2003; 198: 679-691.
70. Peh CA, Burrows SR, Barnden M, et al. HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading. Immunity 1998; 8: 531-542.
71. Purcell AW, Kelly AJ, Peh CA, Dudek NL, McCluskey J. Endogenous and exogenous factors contributing to the surface expression of HLA B27 on mutant APC. Hum Immunol 2000; 61: 120-130.
72. Williams AP, Peh CA, Purcell AW, McCluskey J, Elliott T. Optimization of the MHC class I peptide cargo is dependent on tapasin. Immunity 2002; 16: 509-520.
73. Zernich D, Purcell AW, Macdonald WA, et al. Natural HLA class I polymorphism controls the pathway of antigen presentation and susceptibility to viral evasion. J Exp Med 2004; 200: 13-24.
74. Park B, Lee S, Kim E, Ahn K. A single polymorphic residue within the peptide-binding cleft of MHC class I molecules determines spectrum of tapasin dependence. J Immunol 2003; 170: 961-968.
75. Myers NB, Harris MR, Connolly JM, Lybarger L, Yu YY, Hansen TH. K(b), k(d), and L(d) molecules share common tapasin dependencies as determined using a novel epitope Tag [In Process Citation]. J Immunol 2000; 165: 5656-5663.
76. Braud VM, Allan DS, Wilson D, McMichael AJ. TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide. Curr Biol 1998; 8: 1-10.
77. Hickman HD, Luis AD, Buchli R, et al. Toward a definition of self: proteomic evaluation of the class I peptide repertoire. J Immunol 2004; 172: 2944-2952.
78. Tynan FE, Borg NA, Miles JJ, et al. High resolution structures of highly bulged viral epitopes bound to major histocompatibility complex class I. Implications for T-cell receptor engagement and T-cell immunodominance. J Biol Chem 2005; 280: 23900-23909.
79. Guo H-C, Jardetzky TS, Garrett TPJ, Lane WS, Strominger JL, Wiley DC. Diferent length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle. Nature 1992; 360: 364-366.
80. Speir JA, Stevens J, Joly E, Butcher GW, Wilson IA. Two different, highly exposed, bulged structures for an unusually long peptide bound to rat MHC class I RT1-Aa. Immunity 2001; 14: 81-92.
81. Probst-Kepper M, Hecht HJ, Herrmann H, et al. Conformational restraints and flexibility of 14-meric peptides in complex with HLA-B*3501. J Immunol 2004; 173: 5610-5616.
82. Miles JJ, Elhassen D, Borg NA, et al. CTL recognition of a bulged viral peptide involves biased TCR selection. J Immunol 2005; 175: 3826-3834.
83. Ebert LM, Liu YC, Clements CS, et al. A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design. Cancer Res 2009; 69: 1046-1054.
84. Tynan FE, Elhassen D, Purcell AW, et al. The immunogenicity of a viral cytotoxic T cell epitope is controlled by its MHC-bound conformation. J Exp Med 2005; 202: 1249-1260.
85. Tynan FE, Borg NA, Miles JJ, et al. High resolution structures of highly bulged viral epitopes bound to major histocompatibility complex class I: implications for T-cell receptor engagement and T-cell immunodominance. J Biol Chem 2005; 280: 23900-23909.
86. Aguilar JC, Rodriguez EG. Vaccine adjuvants revisited. Vaccine 2007; 25: 3752-3762
87. Kanodia S, Kast WM. Peptide-based vaccines for cancer: realizing their potential. Expert Review of Vaccines 2008; 7: 1533-1545.
88. Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Adv Drug Delivery Rev 2008; 60: 915-928.
89. Sun H-X, Xie Y, Ye Y-P. ISCOMs and ISCOMATRIX(TM). Vaccine 2009; 27: 4388-4401.
90. Maraskovsky E, Schnurr M, Wilson NS, Robson NC, Boyle J, Drane D. Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant. Immunol Cell Biol 2009; 87: 371-376.
91. Chianese-Bullock KA, Pressley J, Garbee C, et al. MAGE-A1-, MAGE-A10-, and gp100-Derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J Immunol 2005; 174: 3080-3086.
92. Markovic SN, Suman VJ, Ingle JN, et al. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. Am J Clin Oncol 2006; 29: 352-360.
93. Lee P, Wang F, Kuniyoshi J, et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 2001; 19: 3836-3847.
94. Kouiavskaia DV, Berard CA, Datena E, et al. Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 -Cell response to the native peptide psa: 154-63 but failed to induce the reactivity against tumor targets expressing PSA: A phase 2 study in patients with recurrent prostate cancer. J Immunother 2009; 32: 655-666
95. Cocco C, Pistoia V, Airoldi I. New perspectives for melanoma immunotherapy: role of IL-12. Curr Mol Med 2009; 9: 459-469.
96. Palena C, Abrams SI, Schlom J, Hodge JW. Cancer vaccines: preclinical studies and novel strategies. Adv Cancer Res 2006; 95: 115-145.
97. Falk K, Rötzschke O, Deres K, Metzger J, Jung G, Rammensee HG. Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast. J Exp Med 1991; 174: 425-434.
98. Sijts AJ, Neisig A, Neefjes J, Pamer EG. Two Listeria monocytogenes CTL epitopes are processed from the same antigen with different efficiencies. J Immunol 1996; 156: 683-692.
99. Rotzschke O, Falk K, Deres K, et al. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 1990; 348: 252-254.
100. Storkus WJ, Zeh HJ, Salter RD, Lotze MT. Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother 1993; 14: 94-103.
101. Storkus WJ, Zeh HJ, Maeurer MJ, Salter RD, Lotze MT. Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J Immunol 1993; 151: 3719-3727.
102. Falk K, Rötzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991; 351: 290-296.
103. Rammensee HG, Falk K, Rotzschke O. Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 1993; 11: 213-244.
104. Williamson NA, Purcell AW. Use of proteomics to define targets of T-cell immunity. Expert Rev Proteomics 2005; 2: 367-380.
105. Purcell AW. Isolation and characterization of naturally processed MHC-bound peptides from the surface of antigen-presenting cells. Methods Mol Biol 2004; 251: 291-306.
106. Purcell AW, Gorman JJ. Immunoproteomics: mass spectrometrybased methods to study the targets of the immune response. Mol Cell Proteomics 2004; 3: 193-208.
107. Urban RG, Chicz RM, Lane WS, et al. A subset of HLA-B27 molecules contains peptides much longer than nonamers. Proc Natl Acad Sci USA 1994; 91: 1534-1538.
108. Prilliman KR, Jackson KW, Lindsey M, Wang J, Crawford D, Hildebrand WH. HLA-B15 peptide ligands are preferentially anchored at their C termini. J Immunol 1999; 162: 7277-7284.
109. Prilliman KR, Lindsey M, Jackson KW, Cole J, Bonner R, Hildebrand WH. Complexity among constituents of the HLA-B*1501 peptide motif. Immunogenetics 1998; 48: 89-97.
110. Hickman HD, Luis AD, Bardet W, et al. Cutting edge: class I presentation of host peptides following HIV infection. J Immunol 2003; 171: 22-26.
111. Hickman HD, Batson CL, Prilliman KR, Crawford DL, Jackson KL, Hildebrand WH. C-terminal epitope tagging facilitates comparative ligand mapping from MHC class I positive cells. Hum Immunol 2000; 61: 1339-1346.
112. Purcell AW, Gorman JJ. The use of post-source decay in matrixassisted laser desorption/ionisation mass spectrometry to delineate T cell determinants. J Immunol Methods 2001; 249: 17-31.
113. Yague J, Marina A, Vazquez J, Lopez De Castro JA. Major histocompatibility complex class I molecules bind natural peptide ligands lacking the amino-terminal binding residue in vivo. J Biol Chem 2001; 276: 43699-43707.
114. Admon A, Barnea E, Ziv T. Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides. Mol Cell Proteomics 2003; 2: 388-398.
115. Luckey CJ, Marto JA, Partridge M, et al. Differences in the expression of human class I MHC alleles and their associated peptides in the presence of proteasome inhibitors. J Immunol 2001; 167: 1212-1221.
116. Sette A, Vitiello A, Reherman B, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994; 153: 5586-5592.
117. Sette A, Fikes J. Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol 2003; 15: 461-470.
118. Slansky JE, Rattis FM, Boyd LF, et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 2000; 13: 529-538.
119. Butler NS, Theodossis A, Webb AI, et al. Structural and biological basis of CTL escape in coronavirus-infected mice. J Immunol 2008; 180: 3926-3937.
120. Dyall R, Bowne WB, Weber LW, et al. Heteroclitic immunization induces tumor immunity. J Exp Med 1998; 188: 1553-1561.
121. Du AP, Limal D, Semetey V, et al. Structural and immunological characterisation of heteroclitic peptide analogues corresponding to the 600-612 region of the HIV envelope gp41 glycoprotein. J Mol Biol 2002; 323: 503-521.
122. Tangri S, Ishioka GY, Huang X, et al. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med 2001; 194: 833-846.
123. Guichard G, Zerbib A, Le Gal FA, et al. Melanoma peptide MART-1(27-35) analogues with enhanced binding capacity to the human class I histocompatibility molecule HLA-A2 by introduction of a beta-amino acid residue: implications for recognition by tumor-infiltrating lymphocytes. J Med Chem 2000; 43: 3803-3808.
124. Reinelt S, Marti M, Dedier S, et al. Beta-amino acid scan of a class I major histocompatibility complex-restricted alloreactive T-cell epitope. J Biol Chem 2001; 276: 24525-24530.
125. Steer DL, Lew RA, Perlmutter P, Smith AI, Aguilar MI. Betaamino acids: versatile peptidomimetics. Curr Med Chem 2002; 9: 811-822.
126. Webb AI, Aguilar MI, Purcell AW. Optimisation of peptide-based cytotoxic T-cell determinants using non-natural amino acids. Lett Pept Sci 2003; 10: 561-569.
127. Marschutz MK, Zauner W, Mattner F, Otava A, Buschle M, Bernkop-Schnurch A. Improvement of the enzymatic stability of a cytotoxic T-lymphocyte-epitope model peptide for its oral administration. Peptides 2002; 23: 1727-1733.
128. Singh-Jasuja H, Emmerich NP, Rammensee HG. The Tubingen approach: identification, selection, and validation of tumorassociated HLA peptides for cancer therapy. Cancer Immunol Immunother 2004; 53: 187-195.
129. Zhang GL, Bozic I, Kwoh CK, August JT, Brusic V. Prediction of supertype-specific HLA class I binding peptides using support vector machines. J Immunol Methods 2007; 320: 143-154.
130. Peters B, Bui HH, Frankild S, et al. A community resource benchmarking predictions of peptide binding to MHC-I molecules. PLoS Comput Biol 2006; 2: e65.
131. Firbas C, Jilma B, Tauber E, et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 2006; 24: 4343-4353.
132. Pietersz GA, Pouniotis DS, Apostolopoulos V. Design of peptidebased vaccines for cancer. Curr Med Chem 2006; 13: 1591-1607.
133. Gentilucci L, Tolomelli A, Squassabia F. Peptides and peptidomimetics in medicine, surgery and biotechnology. Curr Med Chem 2006; 13: 2449-2466.
134. Zhong W, Skwarczynski M, Toth I. Lipid core peptide system for gene, drug, and vaccine delivery. Aust J Chem 2009; 62: 956-967.
135. Eriksson EM, Jackson DC. Recent advances with TLR2-targeting lipopeptide-based vaccines. Curr Protein Pept Sci 2007; 8: 412-417.
136. Petrovsky N. Freeing vaccine adjuvants from dangerous immunological dogma. Expert Rev Vaccines 2008; 7: 7-10.
137. Gricks CS, Gribben JG. Cytotoxic T cell responses against immunoglobulin in malignant and normal B cells: implications for tumor immunity and autoimmunity. Curr Pharm Des 2003; 9(23): 1889-1903.
138. Kanduc D. Self-nonself peptides in the design of vaccines. Curr Pharm Des 2009; 15(28): 3283-3289.
139. Stern LJ, Calvo-Calle JM. HLA-DR: molecular insights and vaccine design. Curr Pharm Des 2009; 15(28): 3249-61.